Basilea Doses First Patient in Phase 1 Trial of BAL2420 Antibiotic, a First-in-Class LptA Inhibitor
Basilea Pharmaceutica, the Swiss commercial-stage anti-infectives company, has dosed the first healthy volunteer in a phase 1 study of the BAL2420 antibiotic, an intravenous inhibitor of lipopolysaccharide transport protein A (LptA). The single-center, randomized, double-blind, placebo-controlled trial employs a single- and multiple-ascending dose design to evaluate safety, tolerability, and pharmacokinetics. The company did not disclose enrolment targets or an expected completion date. CARB-X has funded BAL2420 since 2020, advancing it from hit-to-lead through to this first-in-human study, with additional support from Wellcome and Germany's Federal Ministry of Research, Technology and Space. The press release was issued on March 23, 2026. No AllSci clinical trial listing for BAL2420 was identified at the time of writing.
BAL2420 belongs to a class distinct from every approved antibiotic. LptA forms part of the protein bridge that ferries lipopolysaccharide from the inner membrane to the outer membrane of Gram-negative bacteria, a process without which these organisms cannot survive. Preclinical work has shown that peptidomimetic compounds disrupting this bridge exhibit potent bactericidal activity against drug-resistant Enterobacteriaceae, while a separate 2022 study demonstrated that small molecules blocking the LptA–LptC interaction impair membrane integrity and sensitize bacteria to other agents. A 2024 publication described compounds that trap lipopolysaccharide within its transporter, further validating the Lpt system as druggable. Together these findings provide a rationale for BAL2420's development against multidrug-resistant E. coli and K. pneumoniae, including strains resistant to both beta-lactams and colistin.
Research context
Current treatment of carbapenem-resistant Enterobacteriaceae relies on beta-lactam/beta-lactamase inhibitor combinations such as ceftazidime-avibactam (Pfizer), meropenem-vaborbactam (Melinta), and imipenem-cilastatin/relebactam (Merck), alongside Shionogi's siderophore cephalosporin cefiderocol. Colistin remains a last-resort option but carries dose-limiting nephrotoxicity, and plasmid-mediated resistance to it is spreading. Aztreonam-avibactam (Pfizer/AbbVie), approved in Europe in 2024, addresses metallo-beta-lactamase producers that evade most other combinations, yet it still operates within the beta-lactam scaffold. As analyses of resistance trends have noted, nearly all recent approvals are variations on existing antibiotic classes, leaving the field exposed to cross-resistance. Mortality from carbapenem-resistant bloodstream infections remains high, and the economic fragility of antibiotic developers — several of which have entered bankruptcy despite holding approved products — compounds the problem.